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could demonstrate in TEN-HMS. We had no learning period to
identify appropriate triggers and responses to the new information
being acquired. The analyses they request are only now being done;
the techniques required are complex to apply. We also agree that
remote telemonitoring by people who have little knowledge of the
patient and who are not in a position to offer practical help if
needed is unlikely to be optimal. Telemedicine that integrates care
at the local and regional level is most likely to meet with success.
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Pleiotropic Effects of Statins and Early
Benefit in the PROVE IT–TIMI-22 Study
Ray et al. (1) discuss the early and late benefits of 80 mg/day of
atorvastatin in the acute coronary syndrome patients of the
PROVE IT–TIMI-22 (Pravastatin or Atorvastatin Evaluation
and Infection Trial–Thrombolysis In Myocardial Infarction-22),
and they conclude that the early benefit observed in this trial is
likely due to the pleiotropic effects of the statin used.
Conversely, the difference in the triple end-point incidence they
observe after 30 days, as can be seen in Table 1 of their study, is
limited to patients with plasma low density lipoprotein (LDL)
cholesterol levels 125 mg/dl at randomization (hazard ratio
[HR] 0.31; 95% confidence interval [CI] 0.15 to 0.64; p  0.002),
whereas it is completely absent in patients with LDL cholesterol
125 mg/dl at randomization (HR 0.92; 95% CI 0.63 to 1.36; p
 0.7). It is intriguing that a purported nonlipidic effect of a statin
is observed only in patients with elevated LDL cholesterol.
Pleiotropic effects should, conceptually, exert their protective
properties at any lipid level.
Attribution of the early protective action observed in the
PROVE IT–TIMI-22 trial to the pleiotropic effects of the statin
used should be, in our opinion, more cautious. In actuality, a clear
demonstration of the clinical relevance of these effects is still
lacking. A recent meta-regression of published clinical trials
testing different hypolipidemic treatments concludes that choles-
terol reduction is likely to be the major (or unique) determinant of
coronary heart disease and stroke events reduction (2).
Indeed, LDL reduction obtained by a single LDL apheresis
markedly reduces C-reactive protein and ameliorates the endothe-
lial function of coronary arteries (3), suggesting that LDL reduc-
tion, by itself, can rapidly translate into a variety of biochemical or
clinical benefits. Perhaps we should abandon the concept of
“pleiotropic effects of statins” in favor of that of “pleiotropic effects
of cholesterol reduction.”
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REPLY
We thank Drs. Poli and Pujia for their interest in our report (1). They
suggest that the more significant reduction in clinical events observed
among patients with a high low-density lipoprotein cholesterol
(LDL-C) versus those with a low LDL-C at baseline provides
evidence that the early benefits observed at 30 days are related more to
lipids than any potential pleiotropic effects. Acute coronary syndrome
(ACS) patients have a high early recurrence of adverse events after
ACS. The significant early benefits of intensive statin therapy ob-
served by day 30 in the PROVE IT–TIMI-22 (Pravastatin or
Atorvastatin Evaluation and Infection Therapy–Thrombolysis In
Myocardial Infarction-22) trial seem more striking when compared to
the benefits of intensive LDL-C reduction by ileal bypass in the
POSCH (Program on the Surgical Control of the Hyperlipidemias)
study, which took nearly seven years to translate into clinical benefit
(2). Similarly, in the early statin trials in stable coronary artery disease
(CAD) the benefits of statins were observed after one to two years,
suggesting that in stable patients the benefits of modest reductions in
LDL-C take place over a period of years rather than days. Whereas
we agree that LDL-C reduction itself is associated with reductions in
C-reactive protein (CRP) and endothelial function, we have demon-
strated that, independent of achieved LDL-C and other correlates,
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the dose of the statin regimen is a significant determinant of CRP
levels (3).
Several lines of evidence also suggest that the pleiotropic effects
of statins may be as relevant as the LDL-C–dependent effects with
respect to clinical outcomes (4). Comparisons across other ACS
trials provide further insight into the potential mechanisms of early
benefit. For instance, in the A to Z trial (5), there was a greater
LDL-C differential between intensive and moderate statin regi-
mens than in the PROVE IT–TIMI-22 trial. However, unlike the
PROVE IT–TIMI-22 trial, there was no difference in CRP at 30
days between treatments in the A to Z (Aggrastat-to-Zocor) study
and also no early benefit was observed. Similarly, in the MIRACL
(Myocardial Ischemia Reduction with Aggressive Cholesterol
Lowering) study the benefit of intensive statin therapy at four
months was independent of the baseline and six-week LDL-C (6).
Taken together these data suggest that mechanisms other than
LDL-C reduction may contribute to early benefit. The recent
meta-regression that Drs. Poli and Pujia refer to did not include
ACS patients, and it is therefore unclear whether it is applicable to
an ACS population during a short follow-up.
Finally, in an additional analysis among patients alive at day 30
with LDL-C data available in the PROVE IT–TIMI-22 trial, we
observed that the benefits of intensive statin therapy at reducing
myocardial infarction or recurrent ACS in the previous 30 days
were present irrespective of whether LDL-C was above or below
the median at day 30 after adjustment for age, gender, and
diabetes, providing further support for the hypothesis that mech-
anisms beyond intensive LDL-C reduction may play a role in the
early benefits observed (Fig. 1).
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Figure 1. Risk of myocardial infarction (MI) or recurrent acute coronary
syndrome (ACS) within 30 days of index ACS stratified by median day-30
low-density lipoprotein (LDL) cholesterol. HR  hazard ratio.
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